| pubmed-article:16020962 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C0014582 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C0439858 | lld:lifeskim |
| pubmed-article:16020962 | lifeskim:mentions | umls-concept:C0205187 | lld:lifeskim |
| pubmed-article:16020962 | pubmed:issue | 4-6 | lld:pubmed |
| pubmed-article:16020962 | pubmed:dateCreated | 2005-8-16 | lld:pubmed |
| pubmed-article:16020962 | pubmed:abstractText | High-dose epirubicin was shown to be effective in the treatment of inoperable non-small cell lung cancer (NSCLC). Paclitaxel is synergistic to a conventional dose of anthracyclines in the treatment of advanced cancer. A phase II study was designed to test the effectiveness of combining paclitaxel with a conventional dose of epirubicin in inoperable NSCLC patients. | lld:pubmed |
| pubmed-article:16020962 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16020962 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16020962 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16020962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16020962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16020962 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16020962 | pubmed:issn | 0030-2414 | lld:pubmed |
| pubmed-article:16020962 | pubmed:author | pubmed-author:YangPan-ChyrP... | lld:pubmed |
| pubmed-article:16020962 | pubmed:author | pubmed-author:ChengAnn-LiiA... | lld:pubmed |
| pubmed-article:16020962 | pubmed:author | pubmed-author:HsuChih-HungC... | lld:pubmed |
| pubmed-article:16020962 | pubmed:author | pubmed-author:YehKun-HueiKH | lld:pubmed |
| pubmed-article:16020962 | pubmed:author | pubmed-author:Whang-PengJac... | lld:pubmed |
| pubmed-article:16020962 | pubmed:author | pubmed-author:YangChih-Hsin... | lld:pubmed |
| pubmed-article:16020962 | pubmed:author | pubmed-author:ChenMin-ChunM... | lld:pubmed |
| pubmed-article:16020962 | pubmed:author | pubmed-author:YuYu-ChieYC | lld:pubmed |
| pubmed-article:16020962 | pubmed:copyrightInfo | (c) 2004 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:16020962 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16020962 | pubmed:volume | 68 | lld:pubmed |
| pubmed-article:16020962 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16020962 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16020962 | pubmed:pagination | 350-5 | lld:pubmed |
| pubmed-article:16020962 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:meshHeading | pubmed-meshheading:16020962... | lld:pubmed |
| pubmed-article:16020962 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16020962 | pubmed:articleTitle | Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment. | lld:pubmed |
| pubmed-article:16020962 | pubmed:affiliation | Department of Oncology and Cancer Research Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. pcyang@ha.mc.ntu.edu.tw | lld:pubmed |
| pubmed-article:16020962 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16020962 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:16020962 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16020962 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
